BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26165583)

  • 1. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.
    Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Kollmeier M; McBride S; Yamada Y; Zelefsky MJ
    J Urol; 2015 Dec; 194(6):1624-30. PubMed ID: 26165583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.
    Song C; Kang HC; Kim JS; Eom KY; Kim IA; Chung JB; Hong SK; Byun SS; Lee SE
    Strahlenther Onkol; 2015 Oct; 191(10):801-9. PubMed ID: 26159555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage.
    Spratt DE; Vargas HA; Zumsteg ZS; Golia Pernicka JS; Osborne JR; Pei X; Zelefsky MJ
    Eur Urol; 2017 Jan; 71(1):37-43. PubMed ID: 27523595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
    Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Polkinghorn W; McBride S; Kollmeier M; Yamada Y; Zelefsky MJ
    Eur Urol; 2015 Jun; 67(6):1009-1016. PubMed ID: 25308970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer.
    Müller AC; Eckert F; Paulsen F; Zips D; Stenzl A; Schilling D; Alber M; Bares R; Martus P; Weckermann D; Belka C; Ganswindt U
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):263-71. PubMed ID: 26853335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival.
    Nini A; Gandaglia G; Fossati N; Suardi N; Cucchiara V; Dell'Oglio P; Cazzaniga W; Luzzago S; Montorsi F; Briganti A
    Eur Urol; 2015 Nov; 68(5):777-84. PubMed ID: 25959166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferumoxtran-10 MR lymphography for target definition and follow-up in a patient undergoing image-guided, dose-escalated radiotherapy of lymph nodes upon PSA relapse.
    Weidner AM; van Lin EN; Dinter DJ; Rozema T; Schoenberg SO; Wenz F; Barentsz JO; Lohr F
    Strahlenther Onkol; 2011 Mar; 187(3):206-12. PubMed ID: 21347637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.
    Grivas N; Wit E; Pos F; de Jong J; Vegt E; Bex A; Hendricksen K; Horenblas S; KleinJan G; van Rhijn B; van der Poel H
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):347-354. PubMed ID: 28068243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence after radical prostatectomy for organ-confined prostate cancer.
    Scheepe JR; Vis AN; Mickisch GH
    Onkologie; 2003 Aug; 26(4):330-3. PubMed ID: 12972697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer.
    Wang YJ; Huang CY; Hou WH; Wang CC; Lan KH; Chen CH; Yu HJ; Lai MK; Cheng AL; Liu SP; Pu YS; Cheng JC
    World J Surg Oncol; 2015 Nov; 13():312. PubMed ID: 26545980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.
    Vance SM; Stenmark MH; Blas K; Halverson S; Hamstra DA; Feng FY
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):940-6. PubMed ID: 22056069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with external beam radiation.
    Rosser CJ; Chichakli R; Levy LB; Kuban DA; Smith LG; Pisters LL
    J Urol; 2002 Aug; 168(2):536-41. PubMed ID: 12131304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation.
    Critz FA; Tarlton RS; Holladay DA
    Cancer; 1995 May; 75(9):2383-91. PubMed ID: 7536126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.